trial · primary record
Mosunetuzumab
Non-Hodgkin Lymphoma
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 208 |
| Primary completion | 2027-02-28 |
| Primary endpoint | Objective Response Rate (ORR) as Determined by the Independent Review Facility (IRF), According to Lugano Response Criteria 2014 (LRC) Using Positron Emission Tomography-computed Tomography (PET-CT) or CT Scans in Interim Analysis Population (IAP) |
| Registry ID | NCT05171647 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:44.678Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05171647
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.